

Allison C Rosenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6661628/publications.pdf>

Version: 2024-02-01

62
papers

626
citations

840776

11
h-index

713466

21
g-index

62
all docs

62
docs citations

62
times ranked

956
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: Diagnosis and management. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1167-1169.	1.2	7
2	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
3	Primary Effusion Lymphoma: A Clinicopathologic Perspective. <i>Cancers</i> , 2022, 14, 722.	3.7	9
4	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
5	Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. <i>Current Treatment Options in Oncology</i> , 2022, 23, 89-98.	3.0	3
6	Quality of Life and Survivorship in Lymphoma. <i>Current Oncology Reports</i> , 2022, 24, 1113-1120.	4.0	5
7	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6
8	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
9	The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 443-449.	1.4	4
10	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	1.3	6
11	Identifying and Meeting the Needs of Adolescents and Young Adults with Cancer. <i>Current Oncology Reports</i> , 2021, 23, 17.	4.0	21
12	Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with SÅ©zary syndrome. <i>JAAD Case Reports</i> , 2021, 9, 24-27.	0.8	7
13	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¬ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
14	Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. <i>Leukemia and Lymphoma</i> , 2021, 62, 2554-2555.	1.3	24
15	Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapyâ€™A Case Report. , 2021, 3, e0472.		0
16	Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 64.	3.0	3
17	Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. , 2021, 9, e001872.		49
18	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Advances in Radiation Oncology</i> , 2021, 6, 100714.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy. <i>JAAD Case Reports</i> , 2021, 15, 15-18.	0.8	3
20	How to Sequence Therapies in Mycosis Fungoides. <i>Current Treatment Options in Oncology</i> , 2021, 22, 101.	3.0	3
21	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
22	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 969-971.	1.2	4
23	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	1.4	1
24	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	1.4	1
25	Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination. <i>Blood</i> , 2021, 138, 4218-4218.	1.4	2
26	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4479-4479.	1.4	0
27	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
28	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	1.4	1
29	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	1.4	2
30	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
31	Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. <i>JAAD Case Reports</i> , 2020, 6, 19-22.	0.8	3
32	Glucocorticoid-Induced Hypermetabolism in White Adipose Tissue in Cushing Syndrome. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 285-286.	0.8	3
33	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. <i>Journal of Hematopathology</i> , 2020, 13, 231-238.	0.4	7
34	Breast implant-associated anaplastic large cell lymphoma and the obligation of insurance providers. <i>Breast Journal</i> , 2020, 26, 2110-2111.	1.0	1
35	Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3581-3583.	1.3	4
36	Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma. <i>Journal of Hematopathology</i> , 2019, 12, 3-10.	0.4	14

#	ARTICLE	IF	CITATIONS
37	Syngiotropic and folliculotropic mycosis fungoides with mycosis fungoides-associated vasculopathic ulcers. <i>JAAD Case Reports</i> , 2019, 5, 231-233.	0.8	4
38	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
39	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019, 134, 5327-5327.	1.4	4
40	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	1.4	1
41	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	1.4	0
42	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	1.3	5
43	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
44	The Brief Case: The Unexpected Souvenir. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	3
45	Closing the Brief Case: The Unexpected Souvenir. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	1
46	Genomics of aggressive B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 69-74.	2.5	15
47	Pitfall of ¹⁸ F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 396-397.	0.8	2
48	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018, 93, 1220-1226.	4.1	9
49	Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. <i>Respiratory Medicine Case Reports</i> , 2018, 25, 129-132.	0.4	8
50	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	1.7	13
51	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. <i>Blood</i> , 2018, 132, 4838-4838.	1.4	3
52	Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 2977-2977.	1.4	0
53	Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 2847-2847.	1.4	0
54	Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. <i>Blood</i> , 2018, 132, 5384-5384.	1.4	1

#	ARTICLE	IF	CITATIONS
55	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LRâ€CD) for untreated lowâ€grade nonâ€Hodgkin lymphoma requiring therapy. American Journal of Hematology, 2017, 92, 467-472.	4.1	15
56	Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report. Journal of Medical Case Reports, 2017, 11, 45.	0.8	7
57	Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 2017, 12, 207-216.	2.3	10
58	High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Reviews, 2017, 31, 37-42.	5.7	180
59	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (<scp>MLN</scp>8237) and Bortezomib in Relapsed Multiple Myeloma. British Journal of Haematology, 2016, 174, 323-325.	2.5	22
60	Extramedullary Cardiac Multiple Myelomaâ€”A Case Report and Contemporary Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 246-252.	0.4	16
61	Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opinion on Pharmacotherapy, 2014, 15, 1265-1276.	1.8	31
62	The blue man: a novel cutaneous manifestation of systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 156-159.	3.0	2